Foghorn Therapeutics Inc.
FHTXHealthcare|Biotechnology|US
$1.87
-0.04 (-1.84%)
Cash / Share
$2.37
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07551635 SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | Small Cell Lung Cancer | P2 | Recruiting | 20 | Open-label | FHD-286 |
| NCT04891757 FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia | P1 | Active | 144 | Open-label | FHD-286, Low Dose Cytarabine, Decitabine |
| NCT07283094 FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | Acute Myeloid Leukemia, Myelodysplastic Syndrome | P1 | Recruiting | 33 | Open-label | Decitabine, Venetoclax, FHD-286 |
| NCT04879017 FHD-286 in Subjects With Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | P1 | Terminated | 76 | Open-label | FHD-286 |
| NCT04965753 FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Advanced Synovial Sarcoma | P1 | Terminated | 55 | Open-label | FHD-609 |